Wake Forest University

Running trials

• Not yet recruiting

  Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

  NCT06534502· Phase 4· Source

• Recruiting

  Ameliorating Stroke-induced Hemianopia Via Multisensory Training

  NCT05894434· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Source

• Recruiting

  Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit

  NCT07173205· Source

• Recruiting

  Quitting Matters Human Immunodeficiency Virus Hybrid Trial

  NCT06883097· Source

• Recruiting

  A Mobile Intervention to Reduce Pain and Improve Health-III

  NCT06623669· Phase 2· Source

• Active, not recruiting

  mPATH-Cloud for Colorectal Cancer Screening

  NCT06441487· Source

• Recruiting

  Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  NCT06724237· Phase 3· Source

• Recruiting

  STimulation to Activate RespIration

  NCT06832306· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Source

• Recruiting

  Project neuroARTEMIS

  NCT06814275· Source

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Source

• Active, not recruiting

  VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

  NCT06249165· Phase 4· Source

• Recruiting

  Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

  NCT06517186· Source

• Recruiting

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· Phase 3· Source

• Recruiting

  DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

  NCT06525259· Source

• Recruiting

  The Osteoarthritis Prevention Study

  NCT05946044· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· Source

• Active, not recruiting

  Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

  NCT06096337· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· Source

• Recruiting

  Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

  NCT06052826· Phase 2· Source

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Source

• Recruiting

  Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

  NCT05139056· Phase 1· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Source

• Active, not recruiting

  Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

  NCT05626855· Phase 3· Source

• Recruiting

  HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

  NCT05873634· Source

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· Source

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Source

• Active, not recruiting

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· Phase 1· Source

• Active, not recruiting

  Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

  NCT07224139· Source

• Active, not recruiting

  Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

  NCT05120284· Phase 2· Source

• Active, not recruiting

  Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

  NCT05119556· Source

• Recruiting

  Use of CereGate Therapy for Freezing of Gait in PD

  NCT05292794· Source

• Active, not recruiting

  A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

  NCT04455750· Phase 3· Source

• Active, not recruiting

  Automated Imaging Differentiation of Parkinsonism

  NCT05913687· Source

• Active, not recruiting

  Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

  NCT04216316· Phase 1/2· Source

• Recruiting

  Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  NCT03606967· Phase 2· Source

• Active, not recruiting

  Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

  NCT04662255· Phase 3· Source

• Active, not recruiting

  Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

  NCT04484818· Phase 3· Source

• Active, not recruiting

  BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

  NCT04214249· Phase 2· Source

• Active, not recruiting

  BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

  NCT04284787· Phase 2· Source

• Active, not recruiting

  Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04172532· Phase 1/2· Source

• Recruiting

  A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  NCT04511013· Phase 2· Source

• Active, not recruiting

  Revisiting A Mobile Intervention to Reduce Pain and Improve Health

  NCT04655001· Source

• Recruiting

  A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  NCT04251052· Source

• Active, not recruiting

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· Phase 2· Source

• Active, not recruiting

  Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

  NCT04079712· Phase 2· Source

• Active, not recruiting

  Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  NCT03953898· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Parkinson disease3 recruiting
• Colorectal cancer2 recruiting
• Heart failure2 recruiting
• HIV2 recruiting
• Melanoma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Frontotemporal dementia1 recruiting
• Glioblastoma1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Treatment for Migraine and Mood

  NCT05576467· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Source

• Completed

  AF at Home: A Virtual Education Program for Patients With Atrial Fibrillation (AF)

  NCT05810896· Source

• Completed

  Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

  NCT05626634· Phase 2· Source

• Completed

  Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO

  NCT05890274· Source

• Completed

  Adolescents Living With HIV (ALWH): Social Networks, Adherence and Retention

  NCT04077047· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Source

• Recruiting

  Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  NCT05219617· Phase 3· Source

• Completed

  Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

  NCT05364021· Phase 1/2· Source

• Completed

  LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

  NCT04790344· Source

• Completed

  Exploring Outcomes and Characteristics of Myasthenia Gravis 2

  NCT06002945· Source

• Completed

  Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

  NCT03641313· Phase 2· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

  NCT04129931· Phase 2· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· Source

• Completed

  Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

  NCT03963739· Source

• Completed

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· Phase 2· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source

• Completed

  Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

  NCT03375489· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· Source

• Recruiting

  HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Source

• Recruiting

  A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  NCT01351545· Source

Trial sites

• Wake Forest University at Clemmons46 trials
• Wake Forest University35 trials
• Wake Forest University, Implementation Science1 trial
• Wake Forest University School of Medicine18 trials
• Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease246 works · 1 trials
• Obesity183 works · 4 trials
• Stroke134 works · 2 trials
• Heart failure109 works · 4 trials
• Type 2 diabetes70 works · 1 trials
• Multiple myeloma50 works · 3 trials
• Chronic kidney disease47 works · 0 trials
• Asthma46 works · 1 trials
• COPD36 works · 2 trials
• Psoriasis28 works · 0 trials
• Childhood cancers16 works · 5 trials
• Head and neck cancer14 works · 2 trials
• Endometrial cancer13 works · 1 trials
• Myeloproliferative neoplasms12 works · 0 trials
• Sickle cell disease11 works · 0 trials
• Mantle cell lymphoma10 works · 2 trials
• Chronic lymphocytic leukaemia7 works · 2 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 works · 0 trials